Back to Journals » Vascular Health and Risk Management » Volume 6

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia

Authors Sasaki J

Published 2 November 2010 Volume 2010:6 Pages 997—1005

DOI https://doi.org/10.2147/VHRM.S7802

Review by Single-blind

Peer reviewer comments 2


Jun Sasaki
Pharmaceutical Medicine, International University of Health and Welfare Graduate School, Fukuoka, Japan

Abstract: Pitavastatin was first developed in Japan and is expanding the regions in which it is clinically available. A considerable number of clinical studies have been conducted and published to date on the usefulness of pitavastatin for patients with primary hypercholesterolemia or combined dyslipidemia. Pitavastatin demonstrates potent low-density lipoprotein cholesterol reduction at low doses of 1–4 mg/day. It also affects the regression of coronary plaques, as observed in intravascular ultrasound-guided percutaneous coronary intervention studies. Moreover, the persistent, long-term high-density lipoprotein cholesterol elevation observed in the populations treated with pitavastatin is worthy of further attention. The reported improvements in lipid profiles are consistent among the studies conducted in Japan, Korea, Thailand, and Europe. In light of accumulating clinical experience worldwide, pitavastatin is now expected to establish its position for preventing and treating cardiovascular disease.

Keywords: randomized clinical trial, Japan, Korea, Thailand, Europe

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]